EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dual Inhibition of PB2 and JAK2 for Influenza: A Strategy Combining Antiviral and Host-Directed Immune Modulation

Binhao Rong, Yujian Yang, Kunyu Lu, Xingyu Zhou, Peisen Zheng, Xinxin Lin, Yuanmei Wen, Shudong Lin, Xinshan Deng iD, Qifan Zhou iD, Shuwen Liu iD

Molecules · 2026

DOI: 10.3390/molecules31040696 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2026. Verfasst von Binhao Rong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China. Hauptthemen laut MEDLINE: Janus Kinase 2, Antiviral Agents, Viral Proteins, Orthomyxoviridae Infections. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Major scientific and technological projects of Guangdong Province, Post Scientist Fund awarded by Chinese Academy of Traditional Chinese Medicine.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Influenza virus infection remains a major global health burden, with severe disease outcomes driven not only by viral replication but also by excessive host inflammatory responses. Current antiviral therapies predominantly target viral components and fail to adequately control virus-induced hyperinflammation. In this study, we report a dual-target therapeutic strategy integrating direct antiviral activity with host-directed immunomodulation. Using a molecular hybridization approach, we designed and synthesized several dual-target inhibitors simultaneously targeting the influenza virus PB2 cap-binding subunit and host JAK2 kinase. Among them, PB05 emerged as the most promising candidate and was systematically evaluated in vitro and in vivo. PB05 exhibited potent broad-spectrum antiviral activity against influenza A viruses, with nanomolar EC50 values. Mechanistic studies demonstrated that PB05 directly binds to the PB2 cap-binding domain, thereby disrupting viral cap-snatching and RNA synthesis. In parallel, PB05 inhibited JAK–STAT signaling by suppressing STAT2 phosphorylation and downstream ISRE-mediated transcription, leading to a marked reduction in pro-inflammatory cytokine production, including IL-6, IL-1β, and IFN-β, in infected or stimulated immune cells. In a lethal influenza A/PR/8/34 (H1N1) mouse model, oral administration of PB05 at 100 mg/kg (twice daily) markedly decreased lung viral titers, attenuated pulmonary tissue damage and edema, and moderated excessive inflammatory responses. Collectively, these findings identify PB05 as a dual PB2/JAK2 inhibitor that effectively couples antiviral efficacy with immunomodulatory activity, promoting a therapeutic strategy for the treatment of severe influenza and other viral diseases associated with excessive inflammation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase 2Antiviral AgentsViral ProteinsOrthomyxoviridae InfectionsInfluenza, HumanRNA-Dependent RNA PolymeraseAnimalsMiceHumansHost-Directed TherapyDogsSignal TransductionVirus ReplicationInfluenza A virusMadin Darby Canine Kidney Cells

Stichwörter der Autor:innen

JAK-STAT signalingPB2 cap-binding domainanti-inflammatoryantiviraldual-target inhibitorinfluenza virus

Substanzen

Janus Kinase 2Antiviral AgentsViral ProteinsRNA-Dependent RNA Polymerase

Autor:innen und Institutionen

  • Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou 510515, China.
  • Shenzhen Key Laboratory of Small Molecule Drug Discovery and Synthesis, Department of Chemistry, Shenzhen Grubbs Institute and Medi-X Pingshan, Southern University of Science and Technology, Shenzhen 518000, China.
  • Department of Computer Science and Engineering, Southern University of Science and Technology, Shenzhen 518000, China.
  • Hunan Provincial Key Laboratory of the Research and Development of Novel Pharmaceutical Preparations, Changsha Medical University, Changsha 410219, China.
  • NMPA Key Laboratory for Research and Evaluation of Drug Metabolism, Department of Pharmacy, Pingshan Hospital, Southern Medical University, Shenzhen 518100, China.
  • State Key Laboratory of Multi-Organ Injury Prevention and Treatment, MOE Key Laboratory of Infectious Diseases Research in South China, MOE Innovation Center for Medical Basic Research on Inflammation and Immune Related…

ORCID-Profile: Xinshan Deng, Qifan Zhou, Shuwen Liu

Förderung

  • National Natural Science Foundation of China
  • Major scientific and technological projects of Guangdong Province
  • Post Scientist Fund awarded by Chinese Academy of Traditional Chinese Medicine

Zitieren

APA

Rong, B., Yang, Y., Lu, K., Zhou, X., Zheng, P., Lin, X., Wen, Y., Lin, S., Deng, X., Zhou, Q., & Liu, S. (2026). Dual Inhibition of PB2 and JAK2 for Influenza: A Strategy Combining Antiviral and Host-Directed Immune Modulation. Molecules. https://doi.org/10.3390/molecules31040696

Vancouver

Rong B, Yang Y, Lu K, Zhou X, Zheng P, Lin X, et al. Dual Inhibition of PB2 and JAK2 for Influenza: A Strategy Combining Antiviral and Host-Directed Immune Modulation. Molecules. 2026. doi:10.3390/molecules31040696

BibTeX
@article{Rong2026,
  author = {Rong, Binhao and Yang, Yujian and Lu, Kunyu and Zhou, Xingyu and Zheng, Peisen and Lin, Xinxin and Wen, Yuanmei and Lin, Shudong and Deng, Xinshan and Zhou, Qifan and Liu, Shuwen},
  title = {Dual Inhibition of PB2 and JAK2 for Influenza: A Strategy Combining Antiviral and Host-Directed Immune Modulation},
  journal = {Molecules},
  year = {2026},
  doi = {10.3390/molecules31040696}
}
Kostenlos starten →